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Abstract
Background: The role of type I collagen, composed of collagen type I alpha 1 (COL1A1) and collagen type I alpha
2 (COL1A2), has been studied in several cancers. However, the expression of COL1A1 and COL1A2 in malignant,
premalignant, and normal gastric tissues and their clinical significances in gastric cancer have not been elucidated.
Methods: Real-time quantitative PCR was performed in 55 malignant, 27 premalignant, and 19 normal tissues to
measure COL1A1 and COL1A2 messenger RNA (mRNA) expression, and the correlations between COL1A1 and
COL1A2 expression and clinicopathological parameters and patients’ survival rate were analyzed.
Results: We found that COL1A1 mRNA expression was significantly upregulated in premalignant and malignant
tissues than in normal tissues, whereas COL1A2 mRNA expression was significantly higher in malignant tissues than
in premalignant and normal tissues. Moreover, COL1A1 expression was unrelated to clinicopathological parameters,
while COL1A2 expression was positively related to tumor size and depth of invasion. Besides, higher COL1A1 and
COL1A2 expression levels were related to lower overall survival.
Conclusions: We find that COL1A1 might have its potential as a monitoring factor to screen early gastric cancer,
and COL1A1 and COL1A2 might predict poor clinical outcomes in gastric cancer patients.
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Background
Gastric cancer ranks the third most common cause of
cancer-related death and the fifth most common cancer in
the world [1], while most gastric cancer patients are still di-
agnosed at the advanced stage, which means a relatively
poor prognosis of overall survival [2]. Meanwhile, intestinal-
type gastric adenocarcinoma, the most common form of
gastric cancer, progresses through a cascade of gastric
lesions known as Correa’s cascade [3], and the development
from premalignant lesion to cancer is usually a gradual
multi-step process. Thus, it is important to identify early
biomarkers and/or prognostic factors for better outcomes.
Type I collagen, found in most connective tissue and
embryonic tissue [4], is an important member of the colla-
gen family which is a key structural component of the
extracellular matrix. Typically, type I collagen is composed
of two chains of collagen type I alpha 1 (COL1A1) and one
chain of collagen type I alpha 2 (COL1A2) [5]. Recently,
similar to the expressions of other members of the collagen
family which is believed to be involved in carcinogenesis
[6–8], abnormal expression of COL1A1 and COL1A2 has
been reported in several cancers [9–11]. In addition, Zang
et al. [12] indentified that COL1A1 and COL1A2 were
differentially expressed in gastric cancer by complementary
DNA (cDNA) microarray. However, the clinical signifi-
cance of COL1A1 and COL1A2 in gastric cancer remains
unclear, and the expression of COL1A1 and COL1A2 in
normal epithelium, premalignant, and tumor lesions of the
stomach is rarely mentioned.
The present study is to address COL1A1 and COL1A2
messenger RNA (mRNA) expression in malignant, prema-
lignant, and normal tissues using real-time qualitative PCR.
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COL1A2 mRNA expression and clinicopathological param-
eters and overall survival time in gastric cancer.
Methods
Tissue specimens
Fifty-five malignant gastric tissues were collected during
surgery (n = 45) and endoscopy examination (n = 10), while
27 premalignant gastric tissues and 19 normal gastric
tissues were obtained during endoscopy examination in
Sir Run Run Shaw Hospital (Hangzhou, Zhejiang, China).
These gastric tissues were frozen immediately in liquid ni-
trogen and stored at −80 °C until RNA extraction. Written
informed consent was obtained from all individual partici-
pants included in the study, and this research was approved
by the Clinical Research Ethics Committee of Sir Run Run
Shaw Hospital. The clinicopathological parameters in-
cluded age, gender, tumor size, degree of differentiation,
depth of invasion, and lymph node metastasis, and the
follow-up period ranged from 1 to 60 months.
RNA extraction and real-time quantitative PCR
Total RNA was extracted with an RNeasy Mini Kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s
instructions and was reversely transcribed into cDNA
using PrimeScriptTM RT reagents kit (Takara, Japan).
Real-time quantitative PCR reactions were performed
using a SYBR® Premix Ex Taq™ kit (Takara, Japan) in a
7500 Real-time PCR System (Applied Biosystems, USA).
The COL1A1-specific primers used were 5′-CTGCTG
GACGTCCTGGTGAA-3′ (forward) and 5′-ACGCTGT
CCAGCAATACCTTGAG-3′ (reverse), and the COL1
A2-specific primers used were 5′-GAGGGCAACAG
CAGGTTCACTTA-3′ (forward) and 5′-TCAGCAC-
CACCGATGTCCAA-3′ (reverse). β-actin was served
as an internal control, and the primers used were 5′-
GTGGCCGAGGACTTTGATTG-3′ (forward) and 5′-
AGTGGGGTGGCTTTTAGGATG-3′ (reverse). The
expression of each gene was normalized to β-actin and
was presented as a relative expression ratio (2−ΔCt, ΔCt
= Cttarget − Ctβ-actin).
Statistical analysis
We assessed the differences of mRNA expression levels
in the three groups and two groups by Kruskal–Wallis
test and Mann–Whitney test, respectively. Correlation
between mRNA expression and clinicopathological
parameters was evaluated by Mann–Whitney test, while
the Kaplan–Meier method was used to plot survival
curves and the differences in survival rate were assessed
by the log-rank test. A two-sided p value less than 0.05
was considered statistically significant. All data were
analyzed using IBM SPSS Statistics 20.
Results
COL1A1 mRNA was significantly overexpressed in
premalignant and malignant tissues, and COL1A2 mRNA
expression was significantly higher in malignant tissues
Since there were significant differences of COL1A1
and COL1A2 expression among malignant, premalig-
nant, and normal tissues, we further assessed the
differences between two groups. As illustrated in
Fig. 1a, COL1A1 mRNA was significantly increased in
premalignant (p = 0.0007) and malignant tissues (p =
0.0019) compared to normal tissues, while no signifi-
cant difference between premalignant and malignant
tissues was observed (p = 0.7826). COL1A2 mRNA
expression was significantly higher in malignant
tissues than that in normal (p < 0.01) and premalig-
nant tissues (p < 0.001), whereas there was no signifi-
cant difference between premalignant and normal
tissues (p = 0.1746) (Fig. 1b).
Fig. 1 Expression of COL1A1 and COL1A2 in malignant,
premalignant, and normal tissues of stomach. a Relative COL1A1
mRNA expression normalized to β-actin in malignant, premalignant,
and normal tissues (**p < 0.01). b Relative COL1A2 mRNA expression
normalized to β-actin in malignant, premalignant, and normal
tissues (**p < 0.01)
Li et al. World Journal of Surgical Oncology  (2016) 14:297 Page 2 of 5
COL1A2 mRNA expression was related to tumor depth of
invasion and tumor size, and there was no relationship
between COL1A1 mRNA expression and
clinicopathological parameters
The correlations between COL1A1 and COL1A2 expres-
sion and clinicopathological parameters were analyzed in
45 gastric cancer patients undergoing surgery. As shown in
Fig. 2a, b, there was no significant correlation between
COL1A1 mRNA expression and clinicopathological param-
eters regarding age, gender, depth of invasion, tumor size,
degree of differentiation, and lymph node status (all p >
0.05), while no significant difference of COL1A2 expression
was observed regarding gender, age, degree of differenti-
ation, and lymph node metastasis (Fig. 2c, d), but COL1A2
expression was higher in the advanced stage and larger
tumor size (p = 0.016 and p = 0.0385, respectively) (Fig. 2d).
High COL1A1 and COL1A2 expression was related to poor
overall survival rate
We divided into two subgroups: low expression (n = 27)
and high expression (n = 28). Univariate analysis by the
Kaplan–Meier plot revealed that the overall survival time
in patients with high COL1A1 expression (mean overall
survival time 33.3 months; range 1–60 months) was sig-
nificantly decreased compared to those with low COL1A1
expression (mean overall survival time 48.8 months; range
2–60 months) (p = 0.004) (Fig. 3a), while a similar result
that patients with low COL1A2 expression (mean overall
survival time 47 months; range 2–60 months) had a better
overall survival rate compared to those with high COL1A2
expression was observed (mean overall survival time
35 months; range 1–60 months) (p = 0.028) (Fig. 3b).
Discussion
Gastric cancer is one of the most aggressive cancers around
the world, but the early diagnosis and overall survival time
remain unfavorable [2]. Thus, identifying new prognostic
factors and/or early tumor biomarkers is useful for better
outcomes. In the present study, we found that COL1A1
and COL1A2 were overexpressed in gastric cancer and
potent prognostic factors by showing their associations with
an adverse prognosis in gastric cancer patients. In addition,
Fig. 2 COL1A2 mRNA expression was related to tumor depth of invasion and tumor size. a COL1A1 mRNA expression was unrelated to
gender, age, and degree of differentiation. b COL1A1 mRNA expression was unrelated to depth of invasion, lymph node metastasis, and
tumor size. c COL1A2 mRNA expression was unrelated to gender, age, and degree of differentiation. d COL1A2 mRNA expression was
significantly related to depth of invasion (*p < 0.05) and tumor size (*p < 0.05) but was unrelated to lymph node metastasis
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COL1A1 might be a potential biomarker for early gastric
cancer diagnosis.
Type I collagen, the major component of fibrillar collagen
family, is believed to be involved in tumor invasion and
progression [8, 13]. However, the expression levels of
COL1A1 and COL1A2 in malignant tumors remain con-
troversial. On one hand, frequent promoter methylation of
COL1A1 was detected in renal cell carcinoma and hepato-
cellular carcinoma [9, 10], and COL1A2 was downregulated
in melanoma [11], head and neck cancer [14], and bladder
cancer [15]. On the other hand, COL1A1 and COL1A2
mRNA was upregulated in colorectal cancer and medullo-
blastoma [16, 17]. Consistent with previous reports [12, 18,
19], the present study demonstrated that COL1A1 and
COL1A2 mRNA expression levels were highly expressed in
gastric cancer specimens compared to normal gastric epi-
thelium by real-time quantitative PCR analysis. In addition,
gastric cancer is usually a multi-step gradual process, and
COL1A1 mRNA expression was significantly higher than
that in normal epithelium but did not significantly change
from premalignant to tumor specimens. COL1A1 has also
been reported to regulate proliferation and migration in
BGC-823 gastric cancer cells [20]. Thus, these results
indicated that COL1A1 may play a role in premalignant
pathogenesis and may have its potential as a monitoring
factor to screen early gastric cancer.
Although the prognosis of gastric cancer largely depends
on the TNM stage at diagnosis [2], predicting patients with
a poor prognosis and providing promising treatments are
helpful for a better outcome. In the present study, we
demonstrate the relationships between clinicopathological
parameters and overall survival time and COL1A1 and
COL1A2 mRNA expression in gastric cancer. No correl-
ation was found between COL1A1 mRNA expression and
the patients’ clinicopathological parameters, which is not
consistent with the previous studies [21–23], while the
overall survival rate was significantly lower in patients with
high COL1A1 expression. The reason why COL1A1
expression did not correlate with depth of invasion and
lymph node metastasis in this study needs to be further ex-
plored. COL1A2 mRNA expression was related to tumor
size and depth of invasion, and high COL1A2 mRNA
expression was positively associated with poor overall sur-
vival time. The present study suggests that COL1A1 and
COL1A2 may be used as prognostic factors. Due to rela-
tively smaller patients’ size, we failed to perform univariate
and multivariate analysis of prognostic factors, and further
studies with larger study sizes are needed to adequately
confirm our result.
Conclusions
We demonstrate that COL1A1 and COLA2 are overex-
pressed in gastric cancer, high COL1A1 might be a moni-
toring factor for early gastric cancer, and high COL1A1 and
COL1A2 mRNA expression could be prognostic factors
predicting overall survival time.
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